Allogene Therapeutics, Inc.

NASDAQ:ALLO

Biotechnology

Healthcare
$0.70 +1.02%

+$0.02 today

Market cap
$241.11M
Beta
0.46
P/E (TTM)
-2.7
EPS (TTM)
-$0.72
52W Low $0.98High $4.46

Volume 10.55M

Average 10.19M

ALLO Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Allogene Therapeutics, Inc.NASDAQ: ALLO

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$2.87M, compared with -$3.1M a year earlier. Trailing-twelve-month gross profit was -$77.25M.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$2.87M or moves back toward the trailing-twelve-month quarterly average of -$19.31M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.87M+6.1% QoQ
Last fiscal yearDec 2025
-$12.36M-56277.3% YoY
LTMMar 2026
-$77.25M+23.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.4%——
1 year-56277.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(12.36M) USD
Year-over-year change
-56277.3%

Gross Profit vs competitors

How ALLO compares with its peers on the latest reported figures

  • ALLO's LTM Mar 2026 gross profit of -$77.25M is the lowest of the 9 companies compared; the peer median is $14.72M.
  • Its year-over-year change of +23.8% is the 5th highest of 9, against a peer median of +14.6%.
ALLO Competitors Peer median
Gross Profit for ALLO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$55.76M +43.8%+80.8%81.9%
DTILPrecision BioSciences, Inc.LTM Mar 2026$43.7M -14.6%+7.9%97.0%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$22.24M -86.1%—96.1%
CELUCelularity Inc.LTM Dec 2025$20.19M -48.5%—76.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$9.26M +117.7%-9.7%82.6%
AUTLAutolus Therapeutics plcLTM Mar 2026-$10.36M +93.0%—11.2%
FATEFate Therapeutics, Inc.LTM Mar 2026-$26.26M +63.7%—415.8%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$29.86M -126.0%+164.4%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$77.25M +23.8%——
Peer median (excluding ALLO) $14.72M+14.6%+44.3%82.6%

Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue114.09M156K95K22K0
Cost of Revenue014.3M0012.36M
Gross Profit114.09M(14.14M)95K22K(12.36M)
Gross Margin100.0%-9063.5%100.0%100.0%—
Research & Development220.18M256.39M242.91M192.3M150.15M
Selling, General & Admin74.11M79.31M71.67M65.21M56.78M
Operating Expenses294.28M321.4M327.83M273.22M194.57M
Depreciation & Amortization10.45M14.3M14.2M13.64M12.36M
EBITDA(171.6M)(326.12M)(313.07M)(243.33M)(177.45M)
EBITDA Margin-150.4%-209050.6%-329543.2%-1106031.8%—
Operating Income(180.19M)(335.54M)(327.74M)(273.2M)(206.93M)
Operating Margin-157.9%-215087.2%-344986.3%-1241813.6%—
Interest Income1.71M4.57M18.31M20.15M19.29M
Interest Expense000181K1.08M
Other Income / Expenses(1.86M)(4.88M)472K16.05M16.05M
Income Before Tax(182.05M)(340.41M)(327.27M)(257.15M)(190.89M)
Pre-Tax Margin-159.6%-218214.1%-344489.5%-1168850.0%—
Income Tax Expense000443K0
Net Income(182.05M)(340.41M)(327.27M)(257.59M)(190.89M)
Net Margin-159.6%-218214.1%-344489.5%-1170863.6%—
EPS (Basic)(1.34)(2.38)(2.09)(1.32)(0.87)
EPS (Diluted)(1.34)(2.38)(2.09)(1.32)(0.87)
Weighted Avg Shares135.82M143.15M156.93M194.81M220.62M
Weighted Avg Shares (Diluted)135.82M143.15M156.93M194.81M220.62M

Allogene Therapeutics, Inc.

NASDAQ:ALLO

Intrinsic Alpha fair value

Locked

Current Price

$0.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.